Audited Standalone and Consolidated Financial Results for quarter and year ended March 31, 2026.
VALIANTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Valiant Laboratories reported strong revenue growth for FY26 with standalone revenue rising 62.8% to ₹21,704.25 lakhs from ₹13,336.18 lakhs in FY25. The standalone business turned profitable with PAT of ₹554.82 lakhs versus a loss of ₹215.02 lakhs in the prior year. However, the consolidated entity shows a different picture with net loss of ₹326.79 lakhs due to its subsidiary Valiant Advanced Sciences dragging down performance. Consolidated revenue grew 78.1% to ₹23,746.75 lakhs. Operating cash flow was negative at ₹1,043.24 lakhs on consolidated basis. The auditors issued un-modified opinions for both standalone and consolidated results.
The standalone results show turnaround from losses to profit, a positive sign for holding company investors. However, the consolidated entity remains in loss territory and burning cash, which could concern group-level investors. The sharp revenue growth and profitability improvement at standalone level are encouraging but the subsidiary losses offset gains.